Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma

BACKGROUND: Both gemcitabine and bexarotene are established single agents for the treatment of cutaneous T-cell lymphoma (CTCL). We investigated the feasibility and efficacy of combining these drugs in a single-arm phase II study. METHODS: Cutaneous T-cell lymphoma patients who had failed standard s...

Descripción completa

Detalles Bibliográficos
Autores principales: Illidge, T, Chan, C, Counsell, N, Morris, S, Scarisbrick, J, Gilson, D, Popova, B, Patrick, P, Smith, P, Whittaker, S, Cowan, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833210/
https://www.ncbi.nlm.nih.gov/pubmed/24136145
http://dx.doi.org/10.1038/bjc.2013.616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833210/
https://www.ncbi.nlm.nih.gov/pubmed/24136145
http://dx.doi.org/10.1038/bjc.2013.616

Ejemplares similares